HC Wainwright Reaffirms Buy Rating for MediWound (NASDAQ:MDWD)

HC Wainwright reissued their buy rating on shares of MediWound (NASDAQ:MDWD) in a research note published on Thursday morning, Benzinga reports. HC Wainwright currently has a $28.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for MediWound’s FY2027 earnings at $1.28 EPS.

A number of other research analysts have also recently issued reports on MDWD. Maxim Group lifted their price objective on MediWound from $25.00 to $30.00 and gave the company a buy rating in a research note on Tuesday, July 16th. StockNews.com raised MediWound to a sell rating in a research report on Monday, August 5th.

MediWound Price Performance

NASDAQ:MDWD opened at $19.27 on Thursday. The firm’s 50-day moving average price is $17.45 and its 200-day moving average price is $16.32. The company has a market capitalization of $178.90 million, a PE ratio of -13.96 and a beta of 0.81. MediWound has a 1-year low of $7.10 and a 1-year high of $24.00.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Wednesday, May 29th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. MediWound had a negative net margin of 64.24% and a negative return on equity of 21.67%. The business had revenue of $4.96 million for the quarter, compared to analysts’ expectations of $4.65 million. Equities analysts anticipate that MediWound will post -1.86 EPS for the current fiscal year.

Hedge Funds Weigh In On MediWound

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Janney Montgomery Scott LLC purchased a new position in shares of MediWound in the first quarter worth $427,000. Yelin Lapidot Holdings Management Ltd. increased its holdings in MediWound by 45.7% in the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock worth $1,276,000 after buying an additional 39,348 shares in the last quarter. Sargent Investment Group LLC raised its position in MediWound by 7.0% in the 4th quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock worth $1,111,000 after buying an additional 7,125 shares during the last quarter. Silverberg Bernstein Capital Management LLC lifted its stake in MediWound by 7.8% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 85,184 shares of the biopharmaceutical company’s stock valued at $1,214,000 after acquiring an additional 6,200 shares during the period. Finally, Rhumbline Advisers purchased a new stake in shares of MediWound during the 2nd quarter valued at about $131,000. 46.83% of the stock is owned by institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.